Table 5.
Demographic and clinical characteristics of the technical and clinical validation cohorts.
| Serial Number | Age (Years) |
BMI (kg/m2) |
Diagnosis | Grade | Stage |
|---|---|---|---|---|---|
| Technical Validation Cohort | |||||
| 20 | 50 | 19 | Control (No endometrial pathology) | ||
| 21 | 52 | 37 | Control (Benign endometrial polyp) | ||
| 22 | 55 | 34 | Control (No endometrial pathology) | ||
| 23 | 56 | 19 | Control (No endometrial pathology) | ||
| 24 | 56 | 37 | Control (No endometrial pathology) | ||
| Clinical Validation Cohort | |||||
| 25 | 58 | 36 | Atypical Hyperplasia | - | - |
| 26 | 67 | 30 | Endometrioid endometrial cancer | 1 | 1A |
| 27 | 55 | 34 | Endometrioid endometrial cancer | 1 | 1A |
| 28 | 50 | 54 | Endometrioid endometrial cancer | 1 | 1A |
| 29 | 62 | 27 | Clear cell | 3 | 1A |
| 30 | 60 | 58 | Control (No endometrial pathology) | - | - |
| 31 | 62 | 24 | Control (Atrophic vaginitis) | - | - |
| 32 | 58 | 30 | Control (Benign endometrial polyp) | - | - |
| 33 | 47 | 24 | Control (No endometrial pathology) | - | - |
| 34 | 52 | 33 | Control (No endometrial pathology) | - | - |